Oncolytics Biotech (OTCMKTS:ONCYF) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Friday.
Oncolytics Biotech (OTCMKTS ONCYF) traded up $0.06 during trading on Friday, hitting $0.68. 374,680 shares of the stock traded hands, compared to its average volume of 138,122. The stock has a market capitalization of $94.54, a P/E ratio of -6.76 and a beta of 1.48. Oncolytics Biotech has a 1-year low of $0.19 and a 1-year high of $0.85.
TRADEMARK VIOLATION WARNING: “Oncolytics Biotech (ONCYF) Raised to “Sell” at ValuEngine” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/05/oncolytics-biotech-oncyf-raised-to-sell-at-valuengine.html.
About Oncolytics Biotech
Oncolytics Biotech Inc is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.